Hard to say, but good to know
Overdose reversal where medetomidine is involved is complicated by the fact that an opioid antagonist (naloxone) isn’t effective.
Select Page
by C. Scott McMillin | Oct 27, 2025 | Addictive Substances | 0 |
Overdose reversal where medetomidine is involved is complicated by the fact that an opioid antagonist (naloxone) isn’t effective.
by C. Scott McMillin | Oct 20, 2025 | Public Health | 0 |
by C. Scott McMillin | Sep 15, 2025 | In the News | 0 |
by C. Scott McMillin | Aug 21, 2025 | In the News | 0 |
by C. Scott McMillin | Aug 11, 2025 | Public Policy | 0 |
by C. Scott McMillin | Jul 24, 2025 | Public Policy | 0 |
by C. Scott McMillin | May 19, 2025 | Public Health | 0 |
I couldn’t help noticing: The lack of references to the effectiveness of interdiction and law-enforcement.
Read Moreby C. Scott McMillin | Apr 21, 2025 | Treatment | 0 |
A user could count on a better exchange rate for the Safer Supply medication, whether in cash or illicit heroin, fentanyl, whatever.
Read Moreby C. Scott McMillin | Mar 20, 2025 | Addictive Substances | 0 |
“Overdose deaths from carfentanil…[increased] from 29 between January and June 2023 to 238 in that same period in 2024.” That’s a heck of a year-over-year increase, although it still represents only a small percentage of total fatalities.
Read Moreby C. Scott McMillin | Dec 19, 2024 | In the News | 0 |
…it appears that a significant percent of the opioid medication is being diverted– for resale on the street, probably, or swapped for the illicit stuff.
Read Moreby C. Scott McMillin | Dec 16, 2024 | Public Policy | 0 |
Right now, and very recently, the curve of overdoses has sloped downward. It’s the first real decline we’ve seen in a long time.
Read Moreby C. Scott McMillin | Oct 21, 2024 | Addiction | 0 |
A logical starting place for a community concerned about drug use would be with data collected by their own health departments and criminal justice agencies, with the aim of funding and implementing a continuum of services that reflects the actual (and likely future) needs of their own citizens.
Read Moreby C. Scott McMillin | Oct 14, 2024 | Treatment | 0 |
These are issues that users seldom take into consideration, in the rush to get the drug. But healthcare professionals, and their attorneys, have to consider them.
Read Moreby C. Scott McMillin | Oct 7, 2024 | Addictive Substances | 0 |
In some instances involving the elderly, the practitioner thinks treatment isn’t worth the effort. “I don’t see the point, especially when she may not have that much time left anyway,”
Read Moreby C. Scott McMillin | Sep 30, 2024 | Prevention | 0 |
Make it a continuing effort, using strategies based in evidence, and harnessing the power of human interaction– instead of relying on a burst of anti-drug education, however intense.
Read Moreby C. Scott McMillin | Sep 19, 2024 | Resources | 0 |
Sounds as if Perry probably wasn’t the only customer, either.
Read Moreby C. Scott McMillin | Sep 2, 2024 | Public Policy | 0 |
At this point in the US, there are allegedly a couple of hundred thousand people who would reasonably qualify as ketamine-addicted.
Read Moreby C. Scott McMillin | Aug 19, 2024 | Addictive Substances | 0 |
Ironically, the same research indicates that those opioids chronic pain patients depended on weren’t really doing much for their pain.
Read More